Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a
three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of
fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the
US. All participants who complete the 12-week randomized trial will be offered open-label
fesoterodine for an additional 9 months.
The hypothesis of the randomized controlled trial is that among women diagnosed with urge
incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean
number of urge incontinence episodes per day.